

# Clinical Trial Protocol

## Iranian Registry of Clinical Trials

31 May 2026

### Effects of vitamin D and omega-3 fatty acids co-supplementation on inflammatory biomarkers, tumor marker CEA, and nutritional status in patients with colorectal cancer

#### Protocol summary

##### Study aim

Evaluation of the effect of vitamin D and omega-3 fatty acids co-supplementation on inflammatory biomarkers, tumor marker CEA, and nutritional status in patients with colorectal cancer

##### Design

An 8 weeks' double blind randomized controlled trial to determine the effects of vitamin D and omega-3 fatty acids co-supplementation on inflammatory biomarkers, tumor marker CEA, and nutritional status in patients with colorectal cancer.

##### Settings and conduct

The participants, who meet the criteria, will be randomly allocated into 4 groups. Blood samples were taken to quantify serum level of 25(OH)D, TNF- $\alpha$ , IL-8, NF-kB, CRP, and tumor marker CEA at study baseline and after 8 weeks of intervention.

##### Participants/Inclusion and exclusion criteria

Inclusion criteria: Patients with stage II or III colorectal cancer if they have to begin chemotherapy; aged 18 years or more; BMI range of 18.5-30 kg/m<sup>2</sup>; not having any chronic disease; no taking vitamin - mineral supplements or parenteral nutrition; not taking laxative, anti-inflammatory and blood thinner medications; absence of allergic to fish and fish products, and history of having other cancers. Exclusion criteria: Affecting by any acute disease during the study; changing the drug regimen; refusing to continue the chemotherapy; unwilling to continue the study; patients who had less than 90% compliance with treatment.

##### Intervention groups

The intervention groups will be randomly allocated into 3 groups: 1) a 50000 IU vitamin D per l, weekly+ 2 omega-3 fatty acid capsules, daily, each capsule containing 330 mg omega-3 fatty acid; 2) a 50000 IU vitamin D per l, weekly+ 2 omega-3 fatty acid placebo, daily; 3) a vitamin D placebo, weekly+ 2 omega-3 fatty

acid capsules.

##### Main outcome variables

Serum level of TNF- $\alpha$ ; tumor marker CEA

#### General information

##### Reason for update

##### Acronym

##### IRCT registration information

IRCT registration number: **IRCT20180306038979N1**

Registration date: **2018-03-16, 1396/12/25**

Registration timing: **prospective**

Last update: **2018-03-16, 1396/12/25**

Update count: **0**

##### Registration date

2018-03-16, 1396/12/25

##### Registrant information

##### Name

Behnaz Abiri

##### Name of organization / entity

##### Country

Iran (Islamic Republic of)

##### Phone

+98 61 3373 8253

##### Email address

abiri.b@ajums.ac.ir

##### Recruitment status

**Recruitment complete**

##### Funding source

##### Expected recruitment start date

2018-05-22, 1397/03/01

##### Expected recruitment end date

2019-05-22, 1398/03/01

##### Actual recruitment start date

empty

**Actual recruitment end date**

empty

**Trial completion date**

empty

**Scientific title**

Effects of vitamin D and omega-3 fatty acids co-supplementation on inflammatory biomarkers, tumor marker CEA, and nutritional status in patients with colorectal cancer

**Public title**

Effects of vitamin D and omega-3 fatty acids co-supplementation on inflammatory biomarkers, tumor marker CEA, and nutritional status in patients with colorectal cancer

**Purpose**

Treatment

**Inclusion/Exclusion criteria****Inclusion criteria:**

Patients with stage II or III colorectal cancer if they have to begin chemotherapy; Aged 18 years or more; BMI range of 18.5-30 kg/m<sup>2</sup>; Serum 25(OH)D < 30 ng/ml; Not having autoimmune disease, diabetes, hypertension, renal, hepatic, parathyroid, and gastrointestinal disorders; No taking vitamin D and/or omega-3 supplements and other vitamin- mineral supplements or parenteral nutrition; Not taking laxative, anti-inflammatory and blood thinner medications; Absence of allergic to fish and fish products, and history of having other cancers.

**Exclusion criteria:**

Affecting by any acute disease during the study; Changing the drug regimen; refusing to continue the chemotherapy; Unwilling to continue the study; Patients who had less than 90% compliance with treatment.

**Age**

From **18 years** old

**Gender**

Both

**Phase**

3

**Groups that have been masked**

- Participant
- Care provider
- Investigator

**Sample size**

Target sample size: **80**

**Randomization (investigator's opinion)**

Randomized

**Randomization description**

Participants were allocated randomly and by using a random number table, into one of four groups. Vitamin D, omega-3, and placebo tablets were placed into identical containers, and a person who is not involved in study protocol created the randomization list. All investigators, and participants were blinded to the random assignments.

**Blinding (investigator's opinion)**

Double blinded

**Blinding description**

For blinding, study leader who is not involved in study protocol created the randomization list assigning participants to the vitamin D, omega-3, or the placebo group. Vitamin D, omega-3, and placebo tablets are placed into unlabeled identical containers. The study leader will label these containers with participant numbers using the randomization list. All investigators, and participants were blinded to the random assignments.

**Placebo**

Used

**Assignment**

Parallel

**Other design features****Secondary Ids**

empty

**Ethics committees****1****Ethics committee****Name of ethics committee**

Ahvaz Jundishapur University of Medical Sciences,

**Street address**

Ahvaz Jundishapur University of Medical Sciences,  
Golestan Highway, Ahvaz, Iran

**City**

Ahvaz

**Province**

Khuzestan

**Postal code**

61357-15794

**Approval date**

2018-03-06, 1396/12/15

**Ethics committee reference number**

IR.AJUMS.REC.1396.1077

**Health conditions studied****1****Description of health condition studied**

Colorectal cancer

**ICD-10 code**

C18.9

**ICD-10 code description**

Malignant neoplasm of colon, unspecified

**Primary outcomes****1****Description**

Serum level of TNF- $\alpha$ .

**Timepoint**

Before and 8 weeks after intervention.

**Method of measurement**

Serum TNF- $\alpha$  levels will be assessed by ELISA and Bender Med kit (Bender Med, Germany).

## Secondary outcomes

### 1

#### Description

Tumor marker CEA.

#### Timepoint

Before and 8 weeks after intervention.

#### Method of measurement

Tumor marker CEA will be assessed by ELISA and CanAg kit (CanAg, Italy).

## Intervention groups

### 1

#### Description

Intervention 1: a 50000 IU vitamin D perl, weekly+ 2 omega-3 fatty acid capsules, daily

#### Category

Treatment - Drugs

### 2

#### Description

Intervention group 2: a 50000 IU vitamin D perl, weekly+ 2 omega-3 fatty acid placebo, daily

#### Category

Treatment - Drugs

### 3

#### Description

Intervention group 3: two omega-3 fatty acid capsules+ a vitamin D placebo, weekly

#### Category

Treatment - Drugs

### 4

#### Description

Control group: a vitamin D placebo, weekly+ 2 omega-3 fatty acid placebo, daily

#### Category

Placebo

## Recruitment centers

### 1

#### Recruitment center

##### Name of recruitment center

Oncology clinic of Tehran Gastroenterology & Hepatology Center (TGHC)

##### Full name of responsible person

Dr. Masood Iravani

##### Street address

Amir Abad, 19th St, No. 144

##### City

Tehran

##### Province

Tehran

#### Postal code

1439963553

#### Phone

+98 21 8801 6980

#### Email

behnaz.abiri@yahoo.com

## Sponsors / Funding sources

### 1

#### Sponsor

##### Name of organization / entity

Ahvaz University of Medical Sciences

##### Full name of responsible person

Dr. Mohammad Badavi

##### Street address

Golestan Highway

##### City

Ahvaz

##### Province

Khuzestan

##### Postal code

61357-15794

##### Phone

+98 61 3336 2414

##### Email

behnaz.abiri@yahoo.com

#### Grant name

#### Grant code / Reference number

#### Is the source of funding the same sponsor organization/entity?

Yes

#### Title of funding source

Ahvaz University of Medical Sciences

#### Proportion provided by this source

100

#### Public or private sector

Public

#### Domestic or foreign origin

Domestic

#### Category of foreign source of funding

*empty*

#### Country of origin

#### Type of organization providing the funding

Academic

## Person responsible for general inquiries

#### Contact

##### Name of organization / entity

Ahvaz University of Medical Sciences

##### Full name of responsible person

Dr. Fatemeh Haidari

##### Position

Associate Professor

##### Latest degree

Ph.D.

##### Other areas of specialty/work

Nutrition

##### Street address

Golestan Highway

**City**  
Ahvaz  
**Province**  
Khouzestan  
**Postal code**  
61357-15794  
**Phone**  
+98 61 3373 8253  
**Email**  
haidari\_f@ajums.ac.ir

## Person responsible for scientific inquiries

### Contact

**Name of organization / entity**  
Iran University of Medical Sciences  
**Full name of responsible person**  
Dr. Mohammadreza Vafa  
**Position**  
Professor  
**Latest degree**  
Ph.D.  
**Other areas of specialty/work**  
Nutrition  
**Street address**  
Hemat Express way  
**City**  
Tehran  
**Province**  
Tehran  
**Postal code**  
61357-15794  
**Phone**  
+98 21 8670 4734  
**Email**  
vafa.m@iums.ac.ir

## Person responsible for updating data

### Contact

**Name of organization / entity**  
Ahvaz University of Medical Sciences  
**Full name of responsible person**  
Behnaz Abiri  
**Position**  
Ph.D. Student  
**Latest degree**  
Master  
**Other areas of specialty/work**  
Nutrition

**Street address**  
Golestan Highway  
**City**  
Ahvaz  
**Province**  
Khouzestan  
**Postal code**  
61357-15794  
**Phone**  
+98 61 3373 8253  
**Email**  
behnaz.abiri@yahoo.com

## Sharing plan

### Deidentified Individual Participant Data Set (IPD)

Yes - There is a plan to make this available

### Study Protocol

Undecided - It is not yet known if there will be a plan to make this available

### Statistical Analysis Plan

Undecided - It is not yet known if there will be a plan to make this available

### Informed Consent Form

Undecided - It is not yet known if there will be a plan to make this available

### Clinical Study Report

Undecided - It is not yet known if there will be a plan to make this available

### Analytic Code

Undecided - It is not yet known if there will be a plan to make this available

### Data Dictionary

Undecided - It is not yet known if there will be a plan to make this available

### Title and more details about the data/document

Primary and secondary outcome measures of the participants.

### When the data will become available and for how long

Starting 1 year after publication.

### To whom data/document is available

People working in academic institutions

### Under which criteria data/document could be used

Using the data in literature review

### From where data/document is obtainable

Email addresses

### What processes are involved for a request to access data/document

Request the data sending email.

### Comments